Griffiths C.E.M. Armstrong A.W. Gudjonsson J.E. J. Bark. Psoriasis Lancet. 397: 1301-1315Parisi R. Iskandar I.Y.K. Kontopantelis E. Augustin M. Griffiths C.E.M. Ashcroft D.M.

National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study.

BMJ. 369: m1590Kaushik S.B. Lebwohl M.G.

Psoriasis: which therapy for which patient: Psoriasis comorbidities and preferred systemic agents.

J. Am. Acad. Dermatol. 80: 27-40

The IL-23/IL-17 axis in inflammation.

J. Clin. Invest. 116: 1218-1222Boyman O. Hefti H.P. Conrad C. Nickoloff B.J. Suter M. Nestle F.O.

Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha.

J. Exp. Med. 199: 731-736Sedger L.M. McDermott M.F.

TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants - past, present and future.

Cytokine Growth Factor Rev. 25: 453-472Dostert C. Grusdat M. Letellier E. Brenner D.

The TNF family of ligands and receptors: communication modules in the immune system and beyond.

Physiol. Rev. 99: 115-160Reich K. Nestle F.O. Papp K. Ortonne J.P. Evans R. Guzzo C. et al.

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.

Lancet. 366: 1367-1374Gottlieb A.B. Merola J.F. Reich K. Behrens F. Nash P. Griffiths C.E.M. et al.

Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.

Br. J. Dermatol. 185: 1124-1134Cessak G. Kuzawińska O. Burda A. Lis K. Wojnar M. Mirowska-Guzel D. et al.

TNF inhibitors - mechanisms of action, approved and off-label indications.

Pharm. Rep. 66: 836-844Calip G.S. Patel P.R. Adimadhyam S. Xing S. Wu Z. Sweiss K. et al.

Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions.

Int. J. Cancer. 143: 1062-1071Fagerli K.M. Kearsley-Fleet L. Mercer L.K. Watson K. Packham J. Symmons D.P.M. et al.

Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register.

Rheumatology. 58: 80-85Atzeni F. Sarzi-Puttini P. Sebastiani M. Panetta V. Salaffi F. Iannone F. et al.

Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA.

Clin. Exp. Rheuma. 37: 649-655Davidson L. Van den Reek J. Van Hunsel F. De Jong E. Kullberg B.J.

Global risk of bacterial skin infections and herpesviridae infections with ustekinumab, secukinumab, and tumour necrosis factor-alpha inhibitors: spontaneous reports of adverse drug reactions from the world health organization pharmacovigilance center.

Acta Derm. Venereol. 102: adv00648Stein Gold L. Papp K. Pariser D. Green L. Bhatia N. Sofen H. et al.

Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.

J. Am. Acad. Dermatol. 86: 77-85Campanaro F. Batticciotto A. Zaffaroni A. Cappelli A. Donadini M.P. Squizzato A.

JAK inhibitors and psoriatic arthritis: a systematic review and meta-analysis.

Autoimmun. Rev. 20102902

Pleuromutilins: potent drugs for resistant bugs-mode of action and resistance.

Cold Spring Harb. Perspect. Med. 7Krueger J.G. McInnes I.B. Blauvelt A.

Tyrosine kinase 2 and Janus kinase3signal transducer and activator of transcription signaling and inhibition in plaque psoriasis.

J. Am. Acad. Dermatol. 86: 148-157van der Fits L. Mourits S. Voerman J.S. Kant M. Boon L. Laman J.D. et al.

Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis.

J. Immunol. 182: 5836-5845Tichy E.M. Hoffman J.M. Suda K.J. Rim M.H. Tadrous M. Cuellar S. et al.

National trends in prescription drug expenditures and projections for 2021.

Am. J. Health Syst. Pharm. 78: 1294-1308Richmond V. Michelini F.M. Bueno C.A. Alché L.E. Ramírez J.A.

Small Molecules as Anti-TNF Drugs.

Curr. Med. Chem. 22: 2920-2942Barlaam B. Bird T.G. Lambert-Van Der Brempt C. Campbell D. Foster S.J. Maciewicz R.

New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.

J. Med. Chem. 42: 4890-4908Conway J.G. Andrews R.C. Beaudet B. Bickett D.M. Boncek V. Brodie T.A. et al.

Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases.

J. Pharm. Exp. Ther. 298: 900-908He M.M. Smith A.S. Oslob J.D. Flanagan W.M. Braisted A.C. Whitty A. et al.

Small-molecule inhibition of TNF-alpha.

Science. 310: 1022-1025Sun W. Wu Y. Zheng M. Yang Y. Liu Y. Wu C. et al.

Discovery of an orally active small-molecule tumor necrosis factor-α inhibitor.

J. Med. Chem. 63: 8146-8156Ma L. Gong H. Zhu H. Ji Q. Su P. Liu P. et al.

A novel small-molecule tumor necrosis factor α inhibitor attenuates inflammation in a hepatitis mouse model.

J. Biol. Chem. 289: 12457-12466Lin Z. Xi L. Chen S. Tao J. Wang Y. Chen X. et al.

Uptake and trafficking of different sized PLGA nanoparticles by dendritic cells in imiquimod-induced psoriasis-like mice model.

Acta Pharm. Sin. B. 11: 1047-1055Tang K.W. Lin Z.C. Wang P.W. Alalaiwe A. Tseng C.H. Fang J.Y.

Facile skin targeting of a thalidomide analog containing benzyl chloride moiety alleviates experimental psoriasis via the suppression of MAPK/NF-κB/AP-1 phosphorylation in keratinocytes.

J. Dermatol. Sci. 99: 90-99Chandrasekharan U.M. Kaur R. Harvey J.E. Braley C. Rai V. Lee M. et al.

TNFR2 depletion reduces psoriatic inflammation in mice by downregulating specific dendritic cell populations in lymph nodes and inhibiting IL-23/IL-17 pathways.

J. Investig. Dermatol.

New pleuromutilin derivatives with enhanced antimicrobial activity.II.Structure-activity correlations.

J. Antibiot. 29: 923-927

Are pleuromutilin antibiotics finally fit for human use?.

Ann. N. Y Acad. Sci. 1241: 71-81Sun F. Zhang H. Gonzales G.B. Zhou J. Li Y. Zhang J. et al.

Unraveling the metabolic routes of retapamulin: insights into drug development of pleuromutilins.

Antimicrob. Agents Chemother. 62

In community-acquired bacterial pneumonia, lefamulin was noninferior to moxifloxacin at 96h after the first dose.

Ann. Intern. Med. 172: Jc22Del Prado-Audelo M.L. Cortés H. Caballero-Florán I.H. González-Torres M. Escutia-Guadarrama L. Bernal-Chávez S.A. et al.

Therapeutic applications of terpenes on inflammatory diseases.

Front. Pharm. 12704197Zhang X. Li H. Feng H. Xiong H. Zhang L. Song Y. et al.

Valnemulin downregulates nitric oxide, prostaglandin E2, and cytokine production via inhibition of NF-kappaB and MAPK activity.

Int. Immunopharmacol. 9: 810-816